💰 Financial Performance

Revenue Growth by Segment

Total revenue grew by 16.86% YoY, reaching INR 82.64 Cr in FY 2024-25 compared to INR 70.72 Cr in FY 2023-24, driven by expansion in the pharmaceutical distribution network.

Geographic Revenue Split

The company operates primarily in the domestic Indian market, specifically Gujarat, contributing 100% of the INR 82.64 Cr revenue, as export segments for South Asian and other global regions reported zero turnover.

Profitability Margins

Profit Before Tax (PBT) margin improved from 4.04% in FY 2023-24 to 4.57% in FY 2024-25, reflecting better operational scaling despite intense competition.

EBITDA Margin

Core profitability at the PBT level stood at 4.57% for FY 2024-25, a YoY increase of 53 basis points from 4.04%, indicating slight improvements in cost management relative to turnover.

Capital Expenditure

Tangible assets were recorded at INR 0.18 Cr as of September 30, 2025, reflecting a low-asset-intensity business model focused on distribution rather than manufacturing.

Credit Rating & Borrowing

The company utilizes significant bank borrowing with sanctioned working capital limits exceeding INR 5.00 Cr; total consolidated borrowings reached INR 54.99 Cr by September 2025.

⚙️ Operational Drivers

Raw Materials

Pharmaceutical formulations and stock-in-trade medicines represent approximately 90-95% of the total cost of goods sold as the company functions as a distributor.

Import Sources

Sourcing is primarily domestic, centered in Gujarat and other Indian pharmaceutical hubs to support the local distribution network.

Key Suppliers

Suppliers include various domestic pharmaceutical manufacturers and multinational players operating within the Indian market.

Capacity Expansion

The company is focused on expanding its distribution reach to underserved regions and leveraging technology to manage a larger volume of inventory across its network.

Raw Material Costs

Purchase of stock-in-trade is the primary cost driver; inventory levels stood at INR 51.61 Cr as of September 2025, representing a significant portion of the working capital cycle.

Manufacturing Efficiency

Not applicable as the company is a distributor; efficiency is measured by inventory turnover and receivable collection cycles.

Logistics & Distribution

Distribution costs are a core operational expense, though specific percentage of revenue was not explicitly broken out in the summary financials.

📈 Strategic Growth

Expected Growth Rate

17%

Growth Strategy

Growth will be achieved by leveraging the National Digital Health Mission for telemedicine integration, expanding the distribution network into underserved rural regions, and utilizing PLI scheme benefits to stabilize input costs through strategic partnerships.

Products & Services

Distribution of pharmaceutical medicines, healthcare products, and formulations to retail and institutional clients.

Brand Portfolio

Mono Pharmacare

New Products/Services

Expansion into digital supply chain services and telemedicine-linked distribution is expected to contribute to future revenue streams.

Market Expansion

Targeting underserved regions in India to capitalize on the increasing healthcare penetration and government-led health initiatives.

Strategic Alliances

The company made investments of INR 7.24 Cr in firms and subsidiaries during FY 2024-25 to strengthen its market position.

🌍 External Factors

Industry Trends

The industry is shifting toward digital inventory management and telemedicine; the company is positioning itself to capitalize on these shifts to improve supply chain efficiency.

Competitive Landscape

The market is fragmented with intense competition from local distributors and increasing pressure from multinational pharmaceutical players.

Competitive Moat

Moat is based on a localized distribution network and regulatory compliance; however, this is challenged by low entry barriers for other large-scale distributors.

Macro Economic Sensitivity

Highly sensitive to government healthcare spending and policies such as the Production Linked Incentive (PLI) scheme which impacts drug availability and cost.

Consumer Behavior

Increasing demand for rapid delivery of medicines and digital healthcare services is driving the need for more agile distribution networks.

Geopolitical Risks

Potential disruptions in the global pharmaceutical supply chain could impact the availability of certain imported formulations.

⚖️ Regulatory & Governance

Industry Regulations

Operations are governed by the Companies Act 2013 and SEBI LODR regulations; the company must also adhere to strict pharmaceutical distribution and storage standards.

Environmental Compliance

Not disclosed; environmental impact is generally lower for distributors than manufacturers.

Taxation Policy Impact

The company faces non-compliance issues with unpaid income tax liabilities totaling INR 1.28 Cr for AY 2024-25 and AY 2025-26.

Legal Contingencies

While management claims no pending litigations, the company has documented non-payment of statutory tax dues amounting to INR 127.67 Lakhs.

⚠️ Risk Analysis

Key Uncertainties

Material deviations in financial reporting to banks (up to INR 5.90 Cr in debtor statements) pose a significant risk to credit credibility and internal control reliability.

Geographic Concentration Risk

100% of revenue is concentrated in the Indian market, primarily within the state of Gujarat, creating high regional dependency.

Third Party Dependencies

High dependency on pharmaceutical manufacturers for consistent supply and maintaining distribution margins.

Technology Obsolescence Risk

Failure to rapidly digitize the supply chain could lead to loss of market share to more tech-enabled competitors.

Credit & Counterparty Risk

Trade receivables of INR 60.99 Cr as of September 2025 indicate high credit exposure to retail pharmacy customers.